Nehal H. Elghazawy Elghazawy

Dr. Nehal H. Elghazawy Elghazawy


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2018 in ACS Infectious Diseases
Verified
Journal Article
Closed access
HMHaroon Mohammad
Haroon Mohammad
NENehal H. Elghazawy Elghazawy
Nehal H. Elghazawy Elghazawy
HEHassan E. Eldesouky
Hassan E. Eldesouky
YHYoussef A. Hegazy
Youssef A. Hegazy
WYWaleed Younis
Waleed Younis
MSMohamed Seleem
Mohamed Seleem

1 January 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ANAbdulkarim Najjar
Abdulkarim Najjar
CPCharlott Platzer
Charlott Platzer
ALAnton Luft
Anton Luft
CAChris Alexander Aßmann
Chris Alexander Aßmann
NENehal H. Elghazawy Elghazawy
Nehal H. Elghazawy Elghazawy
MSMatthias Schmidt
Matthias Schmidt

1 April 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NKNermin Kroush
Nermin Kroush
NENehal H. Elghazawy Elghazawy
Nehal H. Elghazawy Elghazawy
AEAhmed Elhady
Ahmed Elhady
MEMatthias Engel
Matthias Engel
RHRolf W. Hartmann
Rolf W. Hartmann
AAAshraf Abadi
Ashraf Abadi

1 July 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
NENehal H. Elghazawy Elghazawy
Nehal H. Elghazawy Elghazawy
AHAmr Hefnawy
Amr Hefnawy
NSNada K. Sedky
Nada K. Sedky
IEIbrahim M. El-Sherbiny
Ibrahim M. El-Sherbiny
RAReem Arafa
Reem Arafa

22 February 2016 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
NENehal H. Elghazawy Elghazawy
Nehal H. Elghazawy Elghazawy
MEMatthias Engel
Matthias Engel
RHRolf W Hartmann
Rolf W Hartmann
MHMostafa M. Hamed
Mostafa M. Hamed
NKNermin Kroush
Nermin Kroush
AAAshraf Abadi
Ashraf Abadi
Background: Tamoxifen (TAM) is metabolized to the more active 4-hydroxytamoxifen by CYP2D6 enzyme. Due to the genetic polymorphisms in CYP2D6, clinical outcomes of TAM treatment vary. Novel flexible TAM analogs with altered activation pathway were synthesized and were tested for their antiproliferative action on MCF-7 cell lines and their binding affinity for ERα and ERβ. Results: All compounds showed better antiproliferative activity than TAM. Compound 3 showed 80-times more ERα binding than TAM, 900-times more selectivity toward ERα. Compound 3 was tested on the entire National Cancer Institute cancerous cell lines; results indicated a broad spectrum anticancer activity. Conclusion: The novel analogs were more potent than TAM with higher selectivity toward ERα and with potential metabolic stability toward CYP2D6.

2 August 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
HAHazem Ahmed
Hazem Ahmed
LGLivio Gisler
Livio Gisler
NENehal H. Elghazawy Elghazawy
Nehal H. Elghazawy Elghazawy
CKClaudia Keller
Claudia Keller
Wolfgang SipplWolfgang Sippl
Wolfgang Sippl
SASimon Mensah Ametamey
Simon Mensah Ametamey
GluN2B-enriched N-methyl-D-aspartate receptors (NMDARs) are implicated in several neurodegenerative and psychiatric diseases, such as Alzheimer’s disease. No clinically valid GluN1/2B therapeutic exists due to a lack of selective GluN2B imaging tools, and the state-of-the-art [3H]ifenprodil shows poor selectivity in drug screening. To this end, we developed a tritium-labeled form of OF-NB1, a recently reported selective GluN1/2B positron emission tomography imaging (PET) agent, with a molar activity of 1.79 GBq/µmol. The performance of [3H]OF-NB1 and [3H]ifenprodil was compared through head-to-head competitive binding experiments, using the GluN1/2B ligand CP-101,606 and the sigma-1 receptor (σ1R) ligand SA-4503. Contrary to [3H]ifenprodil, the usage of [3H]OF-NB1 differentiated between GluN1/2B and σ1R binding components. These results were corroborated by observations from PET imaging experiments in Wistar rats using the σ1R radioligand [18F]fluspidine. To unravel the binding modes of OF-NB1 and ifenprodil in GluN1/2B and σ1Rs, we performed a retrospective in silico study using a molecular operating environment. OF-NB1 maintained similar interactions to GluN1/2B as ifenprodil, but only ifenprodil successfully fitted in the σ1R pocket, thereby explaining the high GluN1/2B selectivity of OF-NB1 compared to ifenprodil. We successfully showed in a proof-of-concept study the superiority of [3H]OF-NB1 over the gold standard [3H]ifenprodil in the screening of potential GluN1/2B drug candidates.